The FDA has announced its approval for a new Intense Pulsed Light (IPL) device created by Lumenis Ltd that treats dry eye disease.
The Lumenis IPL device uses controlled light-based treatment for symptoms of dry eye disease.
Almost 16 million Americans have been diagnosed with dry eye disease due to meibomian gland dysfunction and it is likely that twice as many are undiagnosed. This is the leading cause of dry eye disease and accounts for almost 86% of cases.
Clinical trials demonstrated that the Lumenis IPL device improved tear breakup time, meibum quality and meibomian gland expressibility as well as a reduction of inflammatory markers. Lumenis has announced that with the approval of the Lumenis IPL they are launching the OptiLight device, which will utilize the Lumenis IPL technology.